Sernova Corp. (TSE:SVA – Get Rating) – Investment analysts at Leede Jones Gab issued their FY2024 earnings estimates for Sernova in a report released on Tuesday, January 10th. Leede Jones Gab analyst D. Loe forecasts that the company will post earnings of ($0.02) per share for the year. The consensus estimate for Sernova’s current full-year earnings is ($0.08) per share. Leede Jones Gab also issued estimates for Sernova’s FY2025 earnings at ($0.01) EPS, FY2026 earnings at ($0.01) EPS and FY2027 earnings at $0.09 EPS.
SVA has been the subject of a number of other reports. Roth Capital reiterated a “buy” rating on shares of Sernova in a report on Tuesday, September 20th. HC Wainwright reissued a “buy” rating and set a C$6.00 price objective on shares of Sernova in a research note on Tuesday.
Sernova Stock Performance
Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection.
- MarketBeat: Week in Review 01/09-01/13
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here’s Why
- Carvana Stock Rally, Here’s What You Need to Know
Receive News & Ratings for Sernova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sernova and related companies with MarketBeat.com's FREE daily email newsletter.